Adjuvant chemotherapy improves survival in patients with completely resected T3N0 non–small cell lung cancer invading the chest wall

Justin A. Drake, Jennifer L. Sullivan, Benny Weksler

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

Objective: Adjuvant chemotherapy prolongs survival in patients with non–small cell lung cancer with N1 disease or tumors larger than 4 cm. Patients with T3N0 disease due to chest wall invasion often receive adjuvant chemotherapy because their disease is classified as stage II non–small cell lung cancer. This study evaluated whether chemotherapy improves survival after complete resection of T3N0 non–small cell lung cancer with invasion of the chest wall. Methods: Patients who underwent complete resection of N0 non–small cell lung cancer with invasion of the chest wall were identified in the National Cancer Database. We performed propensity matching of patients who received adjuvant chemotherapy and patients who did not and examined survival. Results: We identified 2326 eligible patients; 1050 patients (45%) received adjuvant chemotherapy, and 1276 patients (55%) did not. Patients who received chemotherapy after surgery had significantly better median survival than patients who did not (71 vs 39 months, P <.001). We identified 772 matched pairs. In the matched cohort, patients who received chemotherapy after surgery also had significantly better median survival (68 vs 39 months without chemotherapy, P <.001). Conclusions: In this large database study, adjuvant chemotherapy significantly improved survival in patients with T3 (chest wall) N0 non–small cell lung cancer after complete resection. Further studies are required to confirm our findings.

LanguageEnglish (US)
Pages1794-1802
Number of pages9
JournalJournal of Thoracic and Cardiovascular Surgery
Volume155
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Thoracic Wall
Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Survival
Drug Therapy
Databases
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Adjuvant chemotherapy improves survival in patients with completely resected T3N0 non–small cell lung cancer invading the chest wall. / Drake, Justin A.; Sullivan, Jennifer L.; Weksler, Benny.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 155, No. 4, 01.04.2018, p. 1794-1802.

Research output: Contribution to journalArticle

@article{1673731d07ac43758bfc9f9e1a33b828,
title = "Adjuvant chemotherapy improves survival in patients with completely resected T3N0 non–small cell lung cancer invading the chest wall",
abstract = "Objective: Adjuvant chemotherapy prolongs survival in patients with non–small cell lung cancer with N1 disease or tumors larger than 4 cm. Patients with T3N0 disease due to chest wall invasion often receive adjuvant chemotherapy because their disease is classified as stage II non–small cell lung cancer. This study evaluated whether chemotherapy improves survival after complete resection of T3N0 non–small cell lung cancer with invasion of the chest wall. Methods: Patients who underwent complete resection of N0 non–small cell lung cancer with invasion of the chest wall were identified in the National Cancer Database. We performed propensity matching of patients who received adjuvant chemotherapy and patients who did not and examined survival. Results: We identified 2326 eligible patients; 1050 patients (45{\%}) received adjuvant chemotherapy, and 1276 patients (55{\%}) did not. Patients who received chemotherapy after surgery had significantly better median survival than patients who did not (71 vs 39 months, P <.001). We identified 772 matched pairs. In the matched cohort, patients who received chemotherapy after surgery also had significantly better median survival (68 vs 39 months without chemotherapy, P <.001). Conclusions: In this large database study, adjuvant chemotherapy significantly improved survival in patients with T3 (chest wall) N0 non–small cell lung cancer after complete resection. Further studies are required to confirm our findings.",
author = "Drake, {Justin A.} and Sullivan, {Jennifer L.} and Benny Weksler",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.jtcvs.2017.11.091",
language = "English (US)",
volume = "155",
pages = "1794--1802",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Adjuvant chemotherapy improves survival in patients with completely resected T3N0 non–small cell lung cancer invading the chest wall

AU - Drake, Justin A.

AU - Sullivan, Jennifer L.

AU - Weksler, Benny

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Objective: Adjuvant chemotherapy prolongs survival in patients with non–small cell lung cancer with N1 disease or tumors larger than 4 cm. Patients with T3N0 disease due to chest wall invasion often receive adjuvant chemotherapy because their disease is classified as stage II non–small cell lung cancer. This study evaluated whether chemotherapy improves survival after complete resection of T3N0 non–small cell lung cancer with invasion of the chest wall. Methods: Patients who underwent complete resection of N0 non–small cell lung cancer with invasion of the chest wall were identified in the National Cancer Database. We performed propensity matching of patients who received adjuvant chemotherapy and patients who did not and examined survival. Results: We identified 2326 eligible patients; 1050 patients (45%) received adjuvant chemotherapy, and 1276 patients (55%) did not. Patients who received chemotherapy after surgery had significantly better median survival than patients who did not (71 vs 39 months, P <.001). We identified 772 matched pairs. In the matched cohort, patients who received chemotherapy after surgery also had significantly better median survival (68 vs 39 months without chemotherapy, P <.001). Conclusions: In this large database study, adjuvant chemotherapy significantly improved survival in patients with T3 (chest wall) N0 non–small cell lung cancer after complete resection. Further studies are required to confirm our findings.

AB - Objective: Adjuvant chemotherapy prolongs survival in patients with non–small cell lung cancer with N1 disease or tumors larger than 4 cm. Patients with T3N0 disease due to chest wall invasion often receive adjuvant chemotherapy because their disease is classified as stage II non–small cell lung cancer. This study evaluated whether chemotherapy improves survival after complete resection of T3N0 non–small cell lung cancer with invasion of the chest wall. Methods: Patients who underwent complete resection of N0 non–small cell lung cancer with invasion of the chest wall were identified in the National Cancer Database. We performed propensity matching of patients who received adjuvant chemotherapy and patients who did not and examined survival. Results: We identified 2326 eligible patients; 1050 patients (45%) received adjuvant chemotherapy, and 1276 patients (55%) did not. Patients who received chemotherapy after surgery had significantly better median survival than patients who did not (71 vs 39 months, P <.001). We identified 772 matched pairs. In the matched cohort, patients who received chemotherapy after surgery also had significantly better median survival (68 vs 39 months without chemotherapy, P <.001). Conclusions: In this large database study, adjuvant chemotherapy significantly improved survival in patients with T3 (chest wall) N0 non–small cell lung cancer after complete resection. Further studies are required to confirm our findings.

UR - http://www.scopus.com/inward/record.url?scp=85040511496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040511496&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2017.11.091

DO - 10.1016/j.jtcvs.2017.11.091

M3 - Article

VL - 155

SP - 1794

EP - 1802

JO - Journal of Thoracic and Cardiovascular Surgery

T2 - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 4

ER -